Attainment of the anticipated >=50% reduction in LDL-C in the four ACC/AHA guidelines statin benefit groups: A voyager meta-analysis

Abstract

Objectives: Four statin benefit groups were identified by the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines: 1) atherosclerotic cardiovascular disease (ASCVD); 2) baseline LDL-C ≥190 mg/dL; 3) diabetes; and 4) 10-year ASCVD risk ≥7.5% (no ASCVD or diabetes). According to the guidelines, high-intensity statins, rosuvastatin (RSV) 20–40 mg and atorvastatin (ATV) 40–80 mg, are anticipated to reduce LDL-C by ≥50%. Individual patient data (n=32,258) from the VOYAGER meta-analysis of 37 studies are used to analyse the percentage of patients in each statin benefit group who attained ≥50% LDL-C reduction.